clinical trial · NCT04767529
A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
Akero Therapeutics, Inc·phase2·completed·n = 128
NASH - Nonalcoholic SteatohepatitisEfruxiferminPlacebo
brief summary
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in non-cirrhotic subjects with biopsy-proven F2 - F3 NASH.
started
Feb 16, 2021
primary completion
May 2, 2024
completion
May 2, 2024
last updated
Jun 18, 2025
official title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol